User:Mr. Ibrahem/Pazopanib

Pazopanib, sold under the brand name Votrient, is a medication used to treat renal cell carcinoma (RCC) and certain soft tissue sarcoma. In RCC it is used when other treatments have failed. It is taken by mouth.

Common side effects include diarrhea, high blood pressure, white hair, nausea, tiredness, abdominal pain, low blood cells, and liver problems. Other side effects may include low thyroid, QT prolongation, bleeding, blood clots, and gastrointestinal perforation. Use during pregnancy may harm the baby. It is a tyrosine kinase inhibitor.

Pazopanib was approved for medical use in the United States in 2009. In Europe it received conditional approval in 2010 and full approval in 2013. In the United Kingdom it costs the NHS about £2,250 per month as of 2021. In the United States this amount costs about 14,200 USD.